Related Experiment Videos

The complications of intravenous Corynebacterium parvum infusion

Insights

Corynebacterium parvum immunotherapy induced fever and rigors in all patients. While generally well-tolerated, delayed hypotension and herpes labialis were observed, indicating potential transient immunosuppression.

Area of Science:

  • Immunotherapy
  • Oncology
  • Clinical Trials

Background:

  • Corynebacterium parvum (C. parvum) is an immunomodulator used in cancer therapy.
  • Understanding the safety and tolerability profile of C. parvum is crucial for its clinical application.

Purpose of the Study:

  • To evaluate the safety and tolerability of intravenous Corynebacterium parvum in patients undergoing cancer immunotherapy.
  • To document acute and delayed adverse events associated with C. parvum infusions.

Main Methods:

  • 100 intravenous infusions of Corynebacterium parvum were administered to 36 patients at a dose of 5 mg/m2.
  • Adverse events, including fever, rigors, blood pressure changes, and herpes labialis, were systematically recorded.

Main Results:

  • All patients experienced fever and rigors, which were acceptable to most.
  • Seventeen patients had delayed hypotension, severe in eight, but generally well-tolerated.
  • Nine patients experienced herpes labialis after the first infusion, suggesting possible transient immunosuppression.

Conclusions:

  • Intravenous Corynebacterium parvum immunotherapy is associated with acute side effects like fever and rigors.
  • Delayed hypotension and herpes labialis are potential adverse events requiring monitoring.
  • The observed side effects suggest a need for further investigation into the immunomodulatory effects of C. parvum.

Related Concept Videos